OOIR: Observatory of International Research

Papers

(The median citation count of Cancer Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Epidemiology of Triple-Negative Breast Cancer	155
Immunotherapy in Triple-Negative Breast Cancer	42
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy	37
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease	34
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?	34
Cytokine Release Syndrome Biology and Management	31
PARP Inhibitors in Pancreatic Cancer	23
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer	21
Challenges and Errors in Genetic Testing	16
Triple-Negative Breast Cancer	15
Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer	14
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors	14
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer	13
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	13
Immunotherapy Use in Patients With Lung Cancer and Comorbidities	13
DNA Damage Repair Inhibitors—Combination Therapies	12
Fecal Microbiota Transplantation as a Cancer Therapeutic	11
Mechanistic Effects of Estrogens on Breast Cancer	11
DNA Damage Response in Glioblastoma	11
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	10
Hormone Replacement Therapy After Breast Cancer	10
Clinical Targeting of Altered Metabolism in High-Grade Glioma	10
Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?	9
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations	9
Lessons for Oncology From the COVID-19 Pandemic	9

Targeted Treatment of Triple-Negative Breast Cancer	9
Neoantigen-Specific T Cells in Adoptive Cell Therapy	9
The Menopause Management Vacuum	8
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy	8
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	7
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma	7
Epidemiology and Pathogenesis of Myelodysplastic Syndrome	7
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?	7
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	7
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	7
Neurotoxicity Biology and Management	7
The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment	7
Current State of Cell Therapies for Breast Cancer	7
Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?	7
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2	6
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer	6
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers	6
Estrogen for the Treatment and Prevention of Breast Cancer	6
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	6
Circulating Biomarkers in Glioblastoma	6
COVID-19 and Chronic Lymphocytic Leukemia	6
The Gut Microbiome and Pancreatic Cancer Development and Treatment	6
STING Agonists in Head and Neck Squamous Cell Carcinoma	6
Current State of Cell Therapies for Genitourinary Malignancies	6
Moving Immunotherapy Into Early-Stage Lung Cancer	6
Menopausal Hormone Therapy and Breast Cancer	6
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia	6
Overview of Lung Cancer Immunotherapy	6
Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma	6
Telemedicine Across the Cancer Care Continuum	6
Minimal Residual Disease in Multiple Myeloma	6
Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia	5
Integrating New Therapies for Chronic Lymphocytic Leukemia	5
Off-the-Shelf Chimeric Antigen Receptor T Cells	5
Gene Expression Profiles in Cancers and Their Therapeutic Implications	5
Toxicities From Antibody-Drug Conjugates	5
Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine	5
The Biology of Chronic Lymphocytic Leukemia	5
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	5
Autoimmune Cytopenia in CLL	5
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?	5
The Evolving Molecular Landscape of High-Grade Gliomas	5
Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma	4
Diversity and Disparities in Lung Cancer Outcomes Among Minorities	4
Coping Strategies and Their Impact on Emotional Distress and Fatigue Among Breast Cancer Survivors	4
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs	4
Microbiome and Diet in Colon Cancer Development and Treatment	4
Chimeric Antigen Receptor Design Today and Tomorrow	4
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia	4
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?	4

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute	4
Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer	4
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance	4
PARP Inhibition in Advanced Prostate Cancer	4
Chimeric Antigen Receptor T Cells for Multiple Myeloma	4
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer	4
Radiation Therapy and the Microbiome; More Than a Gut Feeling	4
Chimeric Antigen Receptor T-Cell Therapy	4
“Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic”	4
The Microbiome and Liver Cancer	3
The Challenges and Future of Immunotherapy for Gliomas	3
Clinical Evidence Generation During a Pandemic	3
Introduction	3
Improving Equity in Cancer Care in the Face of a Public Health Emergency	3
Updates in the Management of Uveal Melanoma	3
Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas	3
Local Treatment of Triple-Negative Breast Cancer	3
The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances	3
Using Adoptive Cellular Therapy for Localized Protein Secretion	3
Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries	3
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma	3
Monoclonal Antibodies in Myeloma	3
Precision Radiotherapy for Gliomas	3
Transcription Factors and Cancer	3
From Race to Racism and Disparities to Equity	3
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma	3
Cancer Care at the Beginning of the COVID-19 Pandemic	3
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy	3
Diversity in Cancer Care	2
The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment	2
Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints	2
Melanoma—Modern Treatment for Metastatic Melanoma	2
Evolving Landscape of Antibody Drug Conjugates in Lymphoma	2
Neurosurgical Advances for Malignant Gliomas	2
Updates in Classification of Myelodysplastic Syndrome	2
Is Adoptive Cellular Therapy With Non–T-Cell Immune Effectors the Future?	2
Concerns About Compounded Bioidentical Menopausal Hormone Therapy	2
Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma	2
Update on Pregnancy Following Breast Cancer Diagnosis and Treatment	2
Telemedicine and Cancer Care	2
γδ T Cell–Based Adoptive Cell Therapies Against Solid Epithelial Tumors	2
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development	2
Telemedicine and Burnout—How Enhancing Operational Support Can Improve Digital Health Tools	2
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care	2
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia	2
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma	2
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer	2
Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer	2
Human Papillomavirus–Directed Therapeutics for Human Papillomavirus–Associated Oropharyngeal Cancer	2
Genetics of Chronic Lymphocytic Leukemia	2
How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy	2
Immunotherapy for Lung Cancer—Improving Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer With Immunotherapy	2
Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer	2
Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis	2
Emerging Challenges to Cellular Therapy of Cancer	2
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies	2
Targeting HRAS in Head and Neck Cancer	2
Hepatocellular Carcinoma—Southeast Asia Updates	2
How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?	2
Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer	2
Overview of the Management of Higher-Risk Myelodysplastic Syndromes	2
Theranostics in Neuroendocrine Tumors	2
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	2
Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms	2